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Abstract 
Background: Anti-malarial chemoprevention with dihydroartemisinin-piperaquine (DHA/PQ) is a promising tool for 
malaria control, but its efficacy in children may be limited by inadequate drug exposure.
Methods: Children were enrolled in a non directly-observed trial of DHA/PQ chemoprevention in a high transmis-
sion setting in Uganda. Children were randomized at 6 months of age to no chemoprevention (n = 89) or monthly 
DHA/PQ (n = 87) and followed through 24 months of age, with pharmacokinetic sampling performed at variable 
times following monthly dosing of DHA/PQ. A previously published pharmacokinetic model was used to estimate 
piperaquine (PQ) exposure in each child, and associations between PQ exposure and the protective efficacy (PE) of 
DHA/PQ were explored.
Results: The incidence of malaria was 6.83 and 3.09 episodes per person year at risk in the no chemoprevention and 
DHA/PQ arms, respectively (PE 54 %, 95 % CI 39–66 %, P < 0.001). Among children randomized to DHA/PQ, 493 phar-
macokinetic samples were collected. Despite nearly 100 % reported adherence to study drug administration at home, 
there was wide variability in PQ exposure, and children were stratified into three groups based on average PQ exposure 
during the intervention that was determined by model generated percentiles (low, n = 40; medium, n = 37, and high, 
n = 10). Gender and socioeconomic factors were not significantly associated with PQ exposure. In multivariate models, 
the PE of DHA/PQ was 31 % in the low PQ exposure group (95 % CI 6–49 %, P = 0.02), 67 % in the medium PQ expo-
sure group (95 % CI 54–76 %, P < 0.001), and 97 % in the high PQ exposure group (95 % CI 89–99 %, P < 0.001).
Conclusions: The protective efficacy of DHA/PQ chemoprevention in young children was strongly associated with 
higher drug exposure; in children with the highest PQ exposure, monthly DHA/PQ chemoprevention was nearly 
100 % protective against malaria. Strategies to ensure good adherence to monthly dosing and optimize drug expo-
sure are critical to maximize the efficacy of this promising malaria control strategy.
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Background
Despite widespread use of insecticide-treated bednets 
and case management using artemisinin-based combina-
tion therapy (ACT), the incidence of malaria among chil-
dren continues to be very high in many parts of Africa 
[1, 2]. With no vaccine available, malaria control centers 
on vector management and effective use of anti-malarial 
drugs [3]. Insecticide-treated bednets (ITNs) and indoor 
residual spraying (IRS) of insecticides are important, but 
these offer only partial protection, especially in highly 
endemic areas, in part due to worsening insecticide 
resistance [4]. The use of effective drugs to treat malaria 
is critical to control, but in many areas the malaria bur-
den has not improved in recent years [1, 2].
ACT is now the standard therapy for uncomplicated 
falciparum malaria in nearly all areas, due to widespread 
resistance to chloroquine and sulfadoxine-pyrimeth-
amine (SP) [5]. ACT combines a potent, but short-acting 
artemisinin with a longer acting partner drug. Standard 
ACT across Africa is artemether/lumefantrine (AM/LM) 
and artesunate/amodiaquine (AS/AQ), and an alternative 
is dihydroartemisinin/piperaquine (DHA/PQ) [6]. An 
important role for anti-malarials in addition to treatment 
of acute illness is intermittent preventative therapy (IPT), 
the provision of full treatment courses at regular intervals 
to high risk populations. In Africa, IPT is now standard 
practice during pregnancy, with doses of sulfadoxine-
pyrimethamine (SP) each trimester in endemic areas, 
although this strategy is seriously limited by resistance to 
SP [7]. IPT is also recommended in children in some set-
tings (with SP or SP + AQ), but only when resistance to 
SP is uncommon, which limits this practice principally to 
the Sahel subregion [8, 9].
Given widespread resistance to SP in parts of Africa, 
many are considering the use of ACT for IPT, and a logi-
cal choice is DHA/PQ, which provides rapid killing of 
most parasites by DHA and protection for weeks after 
therapy due to the long half-life of PQ [10]. Directly 
observed monthly DHA/PQ offered protective efficacy 
of 98 % against malaria in Thai adults [11]. Likewise, in 
Uganda, directly observed monthly DHA/PQ adminis-
tered to school children 6–14 years of age for 1 year had 
a protective efficacy of 96  % [12]. In contrast, monthly 
DHA/PQ administered without directly observed ther-
apy to children 6–24  months of age had a protective 
efficacy against malaria of 58  % which was significantly 
greater than that of monthly SP or daily trimethoprim-
sulfamethoxazole (TS) [13], but lower than previously 
reported studies in older children and adults. The rea-
sons for this lower efficacy are not clear, but may include 
inadequate drug exposure due to pharmacokinetic (PK) 
distinctions in children, low adherence, and/or lower 
immunity in this younger age range. To investigate the 
magnitude of drug exposure in young children and 
explore the impact of drug exposure on the protective 
efficacy of monthly DHA/PQ, retrospective PK analysis 
was performed using banked plasma samples from this 
randomized clinical trial and associations with the inci-
dence of malaria were evaluated.
Methods
Ethics, consents, and permissions
Informed consent was obtained from the parent or 
guardian of all study participants. Ethical approval was 
obtained from the Uganda National Council of Science 
and Technology, the Makerere University School of Med-
icine Research and Ethics Committee, and the Univer-
sity of California, San Francisco, Committee on Human 
Research.
Study site and participants
A randomized, controlled, open-label trial was con-
ducted in the Tororo District of eastern Uganda, an area 
with intense year round malaria transmission, between 
June 2010 and September 2013. The clinical trial com-
pared the efficacy and safety of three regimens [monthly 
SP, daily trimethoprim-sulfamethoxazole (TS), and 
monthly DHA/PQ] versus no therapy for the prevention 
of malaria in young children, as previously reported [13]. 
Briefly, 400 infants were enrolled and 393 randomized 
at 6 months of age to one of the above treatment arms. 
Chemoprevention was given at home without super-
vision from 6  months through 24  months of age. The 
sub-study described in this report includes only infants 
randomized to DHA/PQ (n = 87) and no chemopreven-
tion (n =  89) who reached 24 months of age. DHA/PQ 
(tablets of 40  mg of dihydroartemisinin and 320  mg of 
piperaquine; Duocotecxin; Holley Pharm), was admin-
istered as a standard regimen each month (once daily 
targeting a total dose of 6.4 and 51.2 mg/kg of dihydroar-
temisinin and piperaquine, respectively, given in three 
equally divided daily doses to the nearest one-quarter 
tablet [6]).
At the time of treatment allocation, parents/guardians 
were given a 2-month supply of DHA/PQ and a diary 
with dates for dosing and check-offs to indicate adminis-
tration. DHA/PQ was resupplied to maintain a 2-month 
supply during clinic visits. Children were permitted to 
eat their meals at flexible times without specifying food 
intake at the time of study dose.
Clinical follow‑up
Clinical follow-up procedures have been previously 
described [13]. Briefly, children were seen in the clinic 
monthly where they underwent routine evaluations 
including thick blood smears, assessment of use of 
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insecticide-treated bednets, and adherence to study 
drugs. Caregivers were instructed to visit the clinic any 
time their child presented with illness. Children who pre-
sented with a fever (tympanic temperature ≥38.0  °C) or 
history of fever in the previous 24 h had blood obtained 
by finger prick for a thick smear. If the thick smear was 
positive for malaria parasites, the patient was diagnosed 
with malaria regardless of parasite density. Episodes of 
uncomplicated malaria were treated with artemether-
lumefantrine, the current first-line treatment in Uganda, 
while episodes of complicated malaria or repeat episodes 
within 14  days of a prior treatment were treated with 
quinine. Following treatment for clinical illness, children 
continued to receive DHA-PQ for chemoprevention at 
their regularly scheduled times, and were not excluded 
from further analysis.
Pharmacokinetic sample collection and PQ concentration 
measurements
All children assigned DHA/PQ provided blood samples 
for PQ quantitation. Samples were collected by phlebot-
omy into EDTA tubes either during a regularly scheduled 
clinic visit performed every 4  months or at the time a 
child presented to the study clinic with clinical malaria. 
All samples were centrifuged within 60  min at 2000×g 
for 10 min; plasma was harvested and transferred to cry-
ovials and stored at −80 °C. Samples were later shipped 
to the Drug Research Unit of the Department of Clinical 
Pharmacy at the University of California San Francisco, 
for determination PQ levels which were analysed using 
liquid chromatography and tandem mass spectrometry, 
using a deuterated PQ (PQ-d6) as an internal standard, as 
previously described [14]. The lower limit of quantifica-
tion (LLOQ) was 1.5 ng/ml and inter- and intra-day vari-
ability was <15 %.
Population pharmacokinetic analysis
PQ concentration measurements were analysed using 
a previously published population pharmacokinetic 
(PK) model generated through a clinical trial investigat-
ing DHA/PQ as treatment for children aged 2–10  years 
from Burkina Faso [15]. Nonlinear mixed effects model-
ling [NONMEM® (version 7.3, Globomaxx LLC, Hano-
ver, MD, USA)] was used to develop the PK model which 
is best described by two-transit-compartments in the 
absorption phase and by a three-compartment model 
in the distribution phase. Briefly, the selected model 
indicated the following parameters: model estimated 
oral clearance (CL/F)  =  7.50  l/h (95  % CI 7.14–7.88), 
median value of apparent total volume of distribution 
(VD/F) = 3850 l (range 1710–7270), median value of half-
life (t1/2) = 23.2 days (range 14.8–31.3) and median value 
of the area under the plasma concentration–time curve 
from time point 0 to day 45 (AUCday0–45) = 36.4 h µg/ml 
(range 9.61–93.0). Since the selected model was based on 
capillary plasma concentrations, venous plasma concen-
trations were converted using a correlation described in 
the modelling paper [15]: ln(Ccapillary) = 0.394 × ln(Cvenous)  
+ 2.702.
Weight was previously shown to be a significant covari-
ate for CL/F and VD/F. Therefore, the same covariate 
approach was used in this current analysis in order to 
adjust for distinctions in the weight ranges between the 
two studies. Weights for the current study ranged from 
6 to 12  kg at the time of PQ sample collection; thus all 
samples were divided in 7 weight strata for 6, 7, 8, 9, 10, 
11 and 12 kg. All clearance and volume parameters were 
allometrically scaled to the mass of the weight strata 
divided by the median value of the population and then 
raised to a power of 0.75 (for clearance) or 1.0 (for vol-
ume) [15]. In this analysis, the median weight value of 
the studied population was obtained by first taking the 
average of the measured weights per child and then the 
median of these average weights. Since weights of chil-
dren varied during the intervention, visual predictive 
checks (VPC) with predicted confidence intervals (2.5–
97.5 %) were simulated for each weight strata during the 
last monthly dosing intervals of the intervention. A rep-
resentative VPC for children in the 9 kg weight strata is 
shown in Additional file 1.
Statistical analysis
PQ exposure scoring system
Based on the population model, PK profiles of PQ were 
simulated for each of the 7 weight strata. In total, 1000 
simulations were run using NONMEM® for each weight 
strata, based on assigned DHA/PQ dosing and PK 
parameters previously generated in children from Bur-
kina Faso [15]. Samples below LLOQ (1.5  ng/ml) were 
allocated half the value of LLOQ, 0.75  ng/ml. For each 
observed PQ concentration, a predicted distribution 
of the observations (at the specific time point when the 
sample was measured) was created. All observed PQ 
concentrations were plotted in their respective predicted 
distribution and assigned a probabilistic value, a percen-
tile, describing how far away each PQ level was from the 
mean of the predicted distributions of observed values 
(Fig. 1). All percentiles were generated through statistical 
computing in the integrated developing environmental 
programme RStudio (version 0.98.1062) for the program-
ming software R (version 3.1.2).
A PQ exposure scoring system was created based on 
the model-generated percentiles for each PQ concen-
tration measurement. Based on the percentile distribu-
tions of each PQ concentration measurement, intervals 
were generated and assigned a PQ exposure score. A 
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percentile of 0 was assigned a score of 0; percentiles from 
0 to ≤20 a score of 1; percentiles >20 to ≤40 a score of 2; 
and percentiles >40 a score of 3 (Fig. 1). The average PQ 
exposure score per child was calculated by dividing the 
sum of a child’s PQ scores by the child’s number of PK 
measurements that were collected during the interven-
tion. Children were then divided into three strata based 
on their average PQ exposure score [0 to <1 (“low”), 1 to 
<2 (“medium”), and >2 (“high”)].
Predictors of PQ exposure and impact on clinical outcomes
All statistical analyses were performed using Prism 6.0 
(GraphPad), R Version 3.1.2, and STATA version 12 
(StataCorp). Descriptive statistics of the study cohort 
included factors associated with malaria risk in this set-
ting [16], including housing structure type, education 
level of the primary care giver, maternal age, and loca-
tion of residence. Comparisons between groups were 
made using the Chi squared test (Table  1). Multivari-
ate linear regression was used to estimate associations 
between predictors of interest and average PQ exposure 
scores in each participant (Table 2). The non-parametric 
Spearman correlation was used to assess the relationship 
between average PQ exposure score as a continuous vari-
able and the incidence of malaria among study partici-
pants randomized to DHA/PQ (Fig. 2).
The protective efficacy of DHA/PQ chemoprevention 
was assessed using a negative binomial regression model, 
stratifying children randomized to DHA/PQ by their aver-
age PQ exposure score (0 to <1, 1 to <2, and ≥2, Table 3). 
The observation period began on the day of randomization 




























Fig. 1 Assigned percentile per collected PK measurement and 
piperaquine exposure scores. Percentiles for each collected plasma 
sample of piperaquine, plotted against the age of the child at 
the time of the measurement. The red text displays the percentile 
boundaries of the piperaquine scores 0, 1, 2 and 3. Solid line repre-
sents best fit relationship between days since start of intervention 
and piperaquine exposure percentile with dotted line showing 95 % 
confidence intervals
Table 1 Descriptive statistics of  study cohort followed 
from 6–24 months of age
DHA/PQ dihydroartemisinin-piperaquine
Characteristic No chemoprevention Monthly DHA/PQ
Number of children fol-
lowed
89 87
Female gender, n (%) 41 (46) 46 (54)
Location of residence, n (%)
 Rural, n (%) 85 (95.5) 79 (90.8)
 Town, n (%) 2 (2.3) 6 (6.9)
 Unknown, n (%) 2 (2.3) 2 (2.3)
Maternal age in years
 16 to <22, n (%) 30 (33.7) 25 (28.7)
 22 to <36, n (%) 53 (59.6) 53 (60.9)
 36 to <45, n (%) 6 (6.7) 9 (10.3)
House construction
 Non-ideal home 81 (91.0) 75 (86.2)
 Ideal home 6 (6.7) 10 (11.5)
 Unknown 2 (2.3) 2 (2.3)
Primary caregiver education
 Primary school or less, 
n (%)
69 (77.5) 74 (85.1)
 More than primary 
school, n (%)
18 (20.2) 11 (62.5)
 Unknown, n (%) 2 (2.3) 2 (2.3)
Table 2 Predictors of piperaquine (PQ) exposure
a All covariates included in multivariate model
b 2 children with unknown location of residence, housing construction, and 
primary caregiver education








 Male 40 1.02 (0.64) Ref Ref
 Female 47 1.11 (0.76) 0.55 0.57
Location of residencea
 Rural 79 1.04 (0.70) Ref Ref
 Town 6 1.13 (0.97) 0.76 0.98
Maternal age in years
 16 to <22 25 1.02 (0.67) Ref Ref
 22 to <36 53 1.02 (0.72) 0.99 0.98
 36 to <45 9 1.46 (0.66) 0.11 0.09
House constructionb
 Non-ideal home 75 1.01 (0.71) Ref Ref
 Ideal home 10 1.33 (0.65) 0.18 0.23
Primary caregiver educationb
 Primary school or less 74 1.03 (0.71) Ref Ref
 More than primary 
school
11 1.11 (0.72) 0.73 0.89
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and ended once the child reached two years of age. Inci-
dent episodes of malaria were defined as all febrile 
episodes accompanied by any parasitemia requiring treat-
ment, but not preceded by another treatment in the prior 
14 days. Time at risk was from the day following the ini-
tiation of study drugs to the last day of observation, minus 
14  days after each treatment for malaria. The incidence 
of malaria was calculated as the number of episodes per 
person years at risk (ppyr). Measures of association were 
expressed as protective efficacy (PE = 1 minus the incident 
rate ratio) during the intervention. Multivariate models 
adjusted for factors associated with malaria risk in this set-
ting, as above. Two-sided p values were calculated for all 
test statistics and P < 0.05 was considered significant.
Results
Study cohort and clinical outcomes
Children were enrolled into a previously described, open-
label clinical trial of anti-malarial chemoprevention [13] 
where the assigned treatment doses were not directly 
observed and administered at home. In this report, chil-
dren randomized to either no chemoprevention or DHA/
PQ and who completed the chemoprevention interven-
tion at 24 months of age were analysed. Of 200 children 
initially enrolled, 89 children randomized to no chemo-
prevention and 87 children randomized to DHA/PQ were 
followed to 24  months of age. Children randomized to 
DHA/PQ had PQ measurements performed serially and 
at variable times during the intervention. Baseline char-
acteristics independently associated with malaria risk in 
this setting, including location of residence, maternal age, 
housing construction type, and primary caregiver educa-
tion [16], were similar between the two groups (Table 1). 
The incidence of malaria in the 89 children randomized 
to no chemoprevention and followed to 24 months of age 
was 6.83 episodes per person year at risk (ppyr), and was 
3.09 episodes ppyr among children randomized to DHA/
PQ (PE 54 %, 95 % CI 38–66 %, P < 0.001). The propor-
tion of assigned DHA/PQ doses reportedly administered 
at home based on diaries completed by primary caregiv-
ers was 99.2 %.
PQ exposure measurements and pharmacokinetic 
modelling
As DHA/PQ was provided at home by a caregiver with-
out direct observation in the clinic, plasma PQ levels 
were measured in banked plasma samples to better esti-
mate PQ exposure. Precise information as to date of sam-
ple collection and the date of when the prior dose was 
scheduled to be administered was available. An average 
of 5.4 samples were collected per child during the period 
of DHA/PQ administration (493 samples total). Of these, 
200 (41 %) samples were collected at times when children 
presented with clinical malaria and 293 (59 %) were col-
lected at variable times post assigned DHA/PQ dose dur-
ing regular routine visits to the clinics. All samples were 
included in the analysis except eight plasma measure-
ments for which there was clear evidence that samples 
were collected immediately after participants took DHA/
PQ off schedule in response to symptoms of malaria.




























Fig. 2 Average piperaquine score and the incidence of malaria. The 
average incidence of malaria per child plotted against the average 
adherence score. Solid line best fit line of generated data with dotted 
line showing 95 % confidence intervals. RS Spearman’s rank correla-
tion
Table 3 Protective efficacy of DHA/PQ when stratified by PQ exposure
DHA/PQ dihydroartemisinin/piperaquine, PYAR person years at risk, PE protective efficacy
a PQ strata based on average PQ exposure score [0 to <1 (“low”), 1 to <2 (“medium”), and >2 (“high”)]
b Multivariate model includes housing location, type, maternal age, and education level of primary care giver





PE (95 % CI) p value PE (95 % CI) p value
No chemoprevention – 89 723 105.9 6.83 – – – –
Low 40 242 50.7 4.77 31 % (5–50 %) 0.023 31 % (6–49 %) 0.017
Monthly DHA/PQ Medium 37 115 50.8 2.26 67 % (53–77 %) <0.001 67 % (54–76 %) <0.001
High 10 3 15.0 0.20 97 % (91–99 %) <0.001 97 % (89–99 %) <0.001
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Pharmacokinetic models were used to estimate PQ 
exposure incorporating time since last DHA/PQ dos-
ing and weight. For each observed PQ concentration, a 
predicted percentile was assigned, and a PQ exposure 
scoring system was created based on this model. Each 
child was assigned an average PQ exposure score and 
children were further stratified into three groups based 
on their average PQ exposure score as described above. 
40 children received an average PQ exposure of 0 to <1 
(“low”), 37 children received an average score of 1 to 
<2 (“medium”) and 10 received an average score of >2 
(“high”) (Fig. 1).
Predictors of PQ exposure
As factors associated with malaria risk may also be asso-
ciated with adherence to the treatment intervention 
and/or drug metabolism, associations between baseline 
characteristics and PQ exposure scores were explored. 
These included gender and markers of socioeconomic 
status, including age and education level of the primary 
caregiver, housing location, and type of housing [16]. In 
both univariate and multivariate analysis, none of these 
indicators were significantly associated with PQ exposure 
(Table 2).
PQ exposure strongly associated with incidence of malaria
Given the variability in PQ scores among children rand-
omized to DHA/PQ, the relationship between PQ expo-
sure and the incidence of malaria among these children 
was determined. Average PQ exposure as a continous 
measure was strongly associated with malaria incidence 
(Fig. 2). Children with the highest average PQ scores had 
significantly less malaria than children with the lowest 
exposure scores (Rs −0.59, P < 0.001).
The protective efficacy of monthly DHA/PQ was then 
estimated for children stratified into three categories 
based on average PQ exposure scores. There was a clear 
dose relationship in protective efficacy with increas-
ing PQ exposure. In univariate analysis, children in the 
“low” PQ exposure strata had 31 % less malaria (95 % CI 
5–50  %); children in the “medium” exposure strata had 
67 % less malaria (95 % CI 53–77 %); and children in the 
“high” exposure strata had 97  % less malaria (95  % CI 
89–99  %) when compared to children given no chemo-
prevention (Table 3). In multivariate analysis controlling 
for factors associated with malaria risk in this setting, the 
results were nearly identical (Table  3). Together, these 
findings suggest that the protective efficacy of DHA/PQ 
chemoprevention in young children is directly related 
to adequate drug exposure, and that in children with the 
highest drug exposure, monthly DHA/PQ is nearly 100 % 
protective against malaria.
Discussion
In this study, the results of a previously published 
clinical trial of monthly DHA/PQ for the prevention 
of malaria in young children were re-analysed, after 
assessment of PQ exposure through serial venous 
plasma PQ measurements in 87 children randomized 
to DHA/PQ. Despite nearly 100  % reported adher-
ence, a wide variability of PQ exposure was observed 
with the majority of values less than expected based on 
a previous model with 89 % of children having model-
generated percentiles averaging ≤40 with the remain-
ing 11 % of children having percentiles averaging >40. 
This variability could not be explained by gender and/
or socioeconomic factors associated with malaria risk 
in this setting. In multivariate models, increasing PQ 
exposure was associated with improved efficacy of 
DHA/PQ, and in children with the highest drug expo-
sure, DHA/PQ chemoprevention was nearly 100 % pro-
tective against malaria.
DHA/PQ is increasingly being considered for IPT in 
several settings. When given as directly observed ther-
apy, monthly DHA/PQ offered protective efficacy of 98 % 
against malaria in Thai adults [11]. Similarly, when given 
as directly observed IPT to Ugandan school children 
6–14  years of age, monthly DHA/PQ had a protective 
efficacy of 96 % in preventing malaria. With PK model-
ling, the protective efficacy of DHA/PQ in Thai adults 
was found to be PQ concentration dependent, with 
plasma PQ trough concentrations of 6.7 and 20  ng/ml 
reducing the hazard of malaria by 50 and 95 %, respec-
tively [17], while during the trial no malaria occured in 
participants with a trough concentration above 31  ng/
ml [11], underscoring the importance of consistent PQ 
exposure.
In this study, significant intersubject variability 
was observed in PQ exposure using serial concentra-
tion measurements made over 2 years of longitudinal 
follow-up. There are several potential reasons for this 
variability. One possibility is inadequate adherence 
with at home study drug administration. Although 
self-reported adherence was nearly 100 %, it is possi-
ble that recall by caregivers was an inadequate meas-
ure of adherence. This is supported by intrasubject 
variability in exposure estimates seen over time for 
some children (data not shown) that would suggest 
inconsistent study drug administration. Another pos-
sibility is that these young children were inadequately 
dosed with DHA/PQ, especially at lower weights. 
Through PK modelling from Thai adults, pharma-
cokinetic simulations for paediatric populations sug-
gest that the incidence of malaria infections over 
1 year could be reduced by 70 % for children weighing 
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8–12  kg if they were administered higher doses than 
currently recommended by the manufacturer [17]. 
The vast majority of children in the present study had 
model generated percentiles of ≤40 utilizing an ear-
lier model stemming from DHA/PQ use in older chil-
dren aged 2–10  years, suggesting that the youngest 
children (<2  years), as enrolled in this study, may be 
inadequately dosed due to pharmacokinetic distinc-
tions for children of different age groups.
Finally, PQ resistance has been reported to increase the 
in  vitro IC50 significantly when resistance was induced 
in vitro [18]. In a recently published study using isolates 
obtained from this clinical trial, ex  vivo drug sensitivity 
decreased for PQ over time [19], although there was not 
clinically relevant evidence for PQ drug resistance in this 
setting, as has been previously reported in other parts 
of Uganda [20]. It is possible that higher PQ exposure is 
needed to offset these changes to provide the best protec-
tion against malaria.
There are some limitations of this study. Since study 
drug administration was not directly observed, it is not 
possible to definitively distinguish between adherence 
versus PK distinctions in very young children as the cause 
for the variability of PQ drug exposure. Future studies of 
PQ pharmacokinetics and the relationship between PK 
exposure and clinical outcomes are now underway in 
very young children receiving directly observed therapy. 
Likewise, although an average of five venous plasma 
measurements in children randomized to DHA/PQ were 
obtained during this study, sampling was variably timed 
following the scheduled day of study drug administration 
which contributed to the variability. Lastly, this analysis 
was dependent on a model generated in older children 
with capillary plasma measurements and measurements 
were from venous plasma samples. Although a published 
correlation equation for older children [15] was used to 
correct for this difference in matrix, the correlation was 
based on samples collected immediately post-dosing 
which may not be applicable to samples collected many 
days post-dosing as done in our study.
Conclusions
In conclusion, the protective efficacy of DHA/PQ chem-
oprevention in young children is directly related to the 
extent of exposure to long acting PQ, and in children 
with the highest PQ exposure, DHA/PQ chemopreven-
tion is nearly 100  % protective against malaria. Strate-
gies to increase PQ concentrations in young children, 
including directly observed therapy or optimized dosing 
guidelines for this distinct patient population, should 
be utilized or developed to improve the efficacy of this 
promising malaria control strategy.
Authors’ contributions
KS, MKM, GD, and FA conceived and designed the study. VB, JK, MMK, and 
LH participated in data collection. KS, RS, PJ, and GD participated in the data 
analysis. All authors participated in the writing of the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala 
University, Uppsala, Sweden. 2 Department of Medicine, San Francisco General 
Hospital, University of California, San Francisco, USA. 3 Department of Clinical 
Pharmacy, University of California, San Francisco, USA. 4 Infectious Diseases 
Research Collaboration, Kampala, Uganda. 5 Department of Bioengineering 
and Therapeutics, University of California, San Francisco, USA. 6 Depart-
ment of Medicine, Makerere University College of Health Sciences, Kampala, 
Uganda. 
Acknowledgements
We are grateful to all the parents and guardians for kindly giving their consent 
and to the study participants for their cooperation. We thank all the members 
of the study team for their tireless effort and excellent work.
Support for this work was provided by NIH/NICHD PO1 HD059454-03; NIH/
NIAID K23 AI100949 (PJ); NIH/NICHD 5R01HD068174-05.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 15 July 2015   Accepted: 15 September 2015
References
 1. Jagannathan P, Muhindo MK, Kakuru A, Arinaitwe E, Greenhouse B, 
Tappero J, et al. Increasing incidence of malaria in children despite 
insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, 
Uganda. Malar J. 2012;11:435. doi:10.1186/1475-2875-11-435.
 2. Mukonka VM, Chanda E, Haque U, Kamuliwo M, Mushinge G, Chileshe J, 
et al. High burden of malaria following scale-up of control interventions 
in Nchelenge District, Luapula Province, Zambia. Malar J. 2014;13:153. 
doi:10.1186/1475-2875-13-153.
 3. Greenwood BM, Bojang K, Whitty CJ, Targett GAT. Malaria. Lancet. 
2005;365:1487–98.
 4. Enayati A, Hemingway J. Malaria management: past, present, 
and future. Annu Rev Entomol. 2010;55:569–91. doi:10.1146/
annurev-ento-112408-085423.
 5. Nosten F, White NJ. Artemisinin-based combination treatment of falcipa-
rum malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181–92.
 6. WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2010.
 7. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine 
resistance on the efficacy of intermittent preventive therapy for malaria 
control during pregnancy: a systematic review. JAMA. 2007;297:2603–16.
Additional file
Additional file 1. Visual predictive check of observed, capillary corrected 
plasma concentrations of piperaquine, measured in children from the 9 kg 
weight strata during the last monthly dosing interval of the intervention. 
Black line represents the 50th percentile, with light grey lines representing 
predicted confidence intervals (2.5 % - 97.5 %). Red points represent the 
observed, capillary corrected plasma concentration of piperaquine. In this 
weight strata, the majority of the observations fall below the 2.5 % limit of 
the confidence interval.
Page 8 of 8Sundell et al. Malar J  (2015) 14:368 
 8. WHO. World malaria report 2012. Geneva: World Health Organization; 
2012.
 9. Konate AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansane A, Soulama I, 
et al. Intermittent preventive treatment of malaria provides substan-
tial protection against malaria in children already protected by an 
insecticide-treated bednet in Burkina Faso: a randomised, double-blind, 
placebo-controlled trial. PLoS Med. 2011;8:e1000408. doi:10.1371/journal.
pmed.1000408.
 10. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, 
et al. Population pharmacokinetics of piperaquine after two different 
treatment regimens with dihydroartemisinin-piperaquine in patients 
with Plasmodium falciparum malaria in Thailand. Antimicrob Agents 
Chemother. 2008;52:1052–61. doi:10.1128/AAC.00955-07.
 11. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, et al. 
Randomized, double-blind, placebo-controlled trial of monthly versus 
bimonthly dihydroartemisinin-piperaquine chemoprevention in adults 
at high risk of malaria. Antimicrob Agents Chemother. 2012;56:1571–7. 
doi:10.1128/AAC.05877-11.
 12. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal 
PJ, et al. Impact of intermittent preventive treatment with dihydroar-
temisinin-piperaquine on malaria in ugandan schoolchildren: a 
randomized, placebo-controlled trial. Clin Infect Dis. 2014;58:1404–12. 
doi:10.1093/cid/ciu150.
 13. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, et al. Pro-
tective efficacy and safety of three antimalarial regimens for the preven-
tion of malaria in young ugandan children: a randomized controlled trial. 
PLoS Med. 2014;11:e1001689. doi:10.1371/journal.pmed.1001689.
 14. Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. Determination 
of the antimalarial drug piperaquine in small volume pediatric plasma 
samples by LC-MS/MS. Bioanalysis. 2014;6:3081–9. doi:10.4155/bio.14.254.
 15. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. 
Population pharmacokinetics and pharmacodynamics of piperaquine 
in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 
2012;91:497–505. doi:10.1038/clpt.2011.254.
 16. Snyman K, Mwangwa F, Bigira V, Kapisi J, Clark TD, Osterbauer B, et al. Poor 
housing construction associated with increased malaria incidence in a 
cohort of young Ugandan children. Am J Trop Med Hyg. 2015;92:1207–
13. doi:10.4269/ajtmh.14-0828.
 17. Bergstrand M, Nosten F, Lwin KM, Karlsson MO, White NJ, Tarning J. 
Characterization of an in vivo concentration-effect relationship for pipe-
raquine in malaria chemoprevention. Sci Transl Med. 2014;. doi:10.1126/
scitranslmed.3005311.
 18. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperaquine resistance is 
associated with a copy number variation on chromosome 5 in drug-pres-
sured Plasmodium falciparum parasites. Antimicrob Agents Chemother. 
2011;55:3908–16. doi:10.1128/AAC.01793-10.
 19. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, 
Nakazibwe C, et al. Impact of antimalarial treatment and chemopreven-
tion on the drug sensitivity of malaria parasites isolated from ugandan 
children. Antimicrob Agents Chemother. 2015;59:3018–30. doi:10.1128/
AAC.05141-14.
 20. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal 
PJ. In vitro sensitivities of Plasmodium falciparum to different antima-
larial drugs in Uganda. Antimicrob Agents Chemother. 2010;54:1200–6. 
doi:10.1128/AAC.01412-09.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
